MARCO ISLAND, Fla. – Complete Genomics said yesterday that it has signed up the Broad Institute of Harvard and MIT to test its human genome sequencing services in a pilot project.
Under the agreement with the Broad, signed earlier this week, Complete Genomics will sequence five human genomes. It is also currently sequencing five human genomes for the Institute for Systems Biology under a partnership established last year.
The company, which plans to sequence a million human genomes over the next five years, also presented — for the first time — data from a human genome that it sequenced in house as a proof of concept.
Last night at the Advances in Genome Biology and Technology conference here, Complete Genomics Chairman, President and CEO Cliff Reid presented results from a HapMap sample that the company completed sequencing last month.
Using its proprietary sequencing-by-probe-ligation technology, Complete Genomics sequenced a Caucasian HapMap sample to 91-fold coverage, generating 630 gigabases worth of short-read paired-end sequence data in nine instrument runs, which take eight days each.
Using internally developed alignment software, company researchers were able to map approximately 250 gigabases of the data to the National Center for Biotechnology Information's human reference genome, covering about 92 percent of the genome.
The company is making the data publicly available through its website and has submitted the sequence reads and base quality scores to NCBI. Later, it hopes to publish the results in a peer-reviewed journal.
Starting in June, Complete Genomics plans to offer a $5,000 commercial human genome sequencing service to genome centers, research institutes, and companies, following a series of pilot projects in the coming months.
By the end of this year, Complete Genomics plans to sequence 1,000 human genomes, and 20,000 next year.
Over the next five years, the company plans to build approximately 10 genome centers across the world in conjunction with partners, and to sequence a million human genomes.
A more comprehensive version of this article is available via GenomeWeb Daily News sister publication In Sequence.